Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry
暂无分享,去创建一个
P. Fenaux | A. Aouba | J. Rossignol | D. Bouscary | A. Mékinian | O. Kosmider | S. Georgin-lavialle | E. Rivière | A. Mathian | J. Vinit | M. Heiblig | L. Terriou | J. Dion | B. Terrier | V. Rieu | G. Le Guenno | T. Comont
[1] D. Kastner,et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. , 2021, Blood advances.
[2] Y. Kirino,et al. Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan , 2021, Annals of the Rheumatic Diseases.
[3] L. Terriou,et al. Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2021, The New England journal of medicine.
[4] S. Mustjoki,et al. Somatic Mutations in "Benign" Disease. , 2021, The New England journal of medicine.
[5] A. Hoischen,et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of VEXAS patients. , 2021, The Journal of allergy and clinical immunology.
[6] N. Young,et al. VEXAS syndrome , 2021, Blood.
[7] P. Evans,et al. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome , 2021, Blood.
[8] E. Clappier,et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease , 2021, Leukemia.
[9] F. Barraco,et al. Therapeutic options in Vexas syndrome: insights from a retrospective series. , 2021, Blood.
[10] J. Mullikin,et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2020, The New England journal of medicine.
[11] N. Vey,et al. Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. , 2019, Autoimmunity reviews.
[12] P. Fenaux,et al. Autoimmune manifestations associated with myelodysplastic syndromes , 2018, Annals of Hematology.
[13] O. Decaux,et al. Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML , 2018 .
[14] S. Scholl,et al. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review , 2014, European journal of haematology.
[15] L. Rink,et al. Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation. , 2014, Immunobiology.
[16] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[17] P. Vyas,et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.
[18] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.